Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Influenza Healthy males and females aged ≥18 and ≤55 years of age at the point of enrolment. 2. Willingness to remain in isolation for the duration of viral shedding and to comply with all study requirements. 3. The following are applicable to subjects in a heterosexual relationship and female subjects in a same sex relationship (i.e., the do not apply to male subjects in a same sex relationship): 1. True abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g. calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception). Or 2. Two forms of effective contraceptive methods among (between) the couple, which are defined as For males: condom with spermicidal foam/gel/film/cream, sterilisation (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate. This applies only to males participating in the study) For females: Women no longer of child bearing potential (post-menopausal females are defined as having a history of amenorrhea for at least 2 years, otherwise they should have documented status as being surgically sterile or post hysterectomy. The latter applies only to females participating in the study). If of childbearing potential, then acceptable forms of contraception Established (a minimum of 2 weeks prior to admission) use of oral, injected or implanted hormonal methods of contraception Placement of an intrauterine device (IUD) or intrauterine system (IUS) Barrier methods of contraception or occlusive cap (diaphragm or cervical/vault caps), both with one of the following spermicidal foam/gel/film/cream/suppository The longevity of contraception is as follows: Males Comply with agreed contraception at entry to quarantine, and continuing until 90 days after the date of viral challenge/last dosing with IMP (whichever occurs last)   Mild to moderate arthritis of non-inflammatory origin may be allowed if the subject is not at risk from relative immobility in the Quarantine Unit and does not require regular medication. 11. A documented medical history for a minimum of the last 2 years prior to inoculation Any subjects who have smoked 10 pack years at any time. Of those subjects that have smoked less than 10 pack years at any time, a subject will be excluded: If regular smokers (e.g., smoking every day) at the time of enrolment. If current casual smoker or use of smoking / nicotine-related products, they must agree to refrain from smoking during the in-patient stay 2. Presence of self-reported or medically documented significant medical condition including but not limited to Chronic pulmonary disease (e.g., asthma (except what is stated in 9), COPD) Chronic cardiovascular disease (e.g., cardiomyopathy, congestive heart failure, cardiac surgery, ischemic heart disease, known anatomic defects) Chronic medical conditions requiring close medical follow-up or hospitalisation during the past 5 years (e.g., insulin dependent diabetes mellitus, renal dysfunction, haemoglobinopathies) Immunosuppression, or immunodeficiency or ongoing malignancy Neurological and neurodevelopmental conditions (e.g., cerebral palsy, epilepsy, stroke, seizures) Post infectious or post vaccine neurological sequelae Hyperlipidemia requiring medical therapy per current American College of Cardiology (ACC) and American Heart Association (AHA) guidelines published in 2013. 3. Individual with body mass index (BMI) <18 and >35. 4. Acute illness within 7 days of first vaccine administration day 5. Clinically significant abnormal electrocardiogram (ECG) and/or parameters, as determined by the Investigator 6. Subjects with clinically significant abnormal systolic and diastolic blood pressure or clinically significant abnormal pulse rate. 7. Subject has abnormal pulmonary function as measured by spirometry defined as a forced vital capacity or forced expiratory volume in 1 second (FEV1) < 80% of predicted or peripheral arterial oxygen saturation (SpO2) < 92% on room air. 8. Known allergy to treatments for influenza (including but not limited to oseltamivir, nonsteroidals). 9. Known allergy to 2 or more classes of antibiotics (e.g. penicillins, cephalosporins, fluoroquinolones, or glycopeptides). Known allergy to excipients in the challenge virus inoculum 10. Daily or household contact with vulnerable populations. 11. Receipt of any investigational drug within 3 months prior to the planned date of Viral Challenge/first dosing with IMP (whichever occurs first)